Lexeo Therapeutics, Inc. reported positive interim Phase 1/2 clinical data for LX2020, a treatment for PKP2-associated arrhythmogenic cardiomyopathy, on January 12, 2026. They will discuss these results in a conference call and webcast on the same date, showcasing their advancements in gene therapy.